# US 2024/0182476 A1 · Diacylglycerol kinase modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0182476 A1
- Document ID: US20240182476A1
- Status: Published application
- Kind: A1
- Application number: 18/450,646
- Filed: 2023-08-16
- Published: 2024-06-06
- Earliest claimed: 2020-12-18
- Assignees: Gilead Sciences, Inc.; Carna Biosciences, Inc.
- Applicants: Gilead Sciences, Inc.; Carna Biosciences, Inc.
- Inventors: Masaaki Sawa; Mai Arai; Ryoko Nakai; Hirokazu Matsumoto; Catherine Pugh; Eric Hu; Juan Guerrero; Jesse Jacobsen; Jonathan William Medley; Jie Xu; Latesh Lad; Leena Patel; Michael Graupe; Qingming Zhu; Stephen Holmbo; Tetsuya Kobayashi; Will Watkins; Yasamin Moazami; Suet C. Yeung; Julian A. Codelli; Heath A. Weaver
- Web page: https://patentgrep.com/patent/US20240182476A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/5545: {having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings}
- A61K 31/695: Silicon compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

## Claims

### Claim at position 1

1-138. (canceled)

### Claim 139

A compound selected from
or a pharmaceutically acceptable salt thereof.

### Claim 140 (depends on 139)

The compound of claim 139, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 141 (depends on 139)

The compound of claim 139, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 142 (depends on 139)

The compound of claim 139, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 143 (depends on 139)

The compound of claim 139, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 144

A compound selected from
or a pharmaceutically acceptable salt thereof.

### Claim 145 (depends on 144)

The compound of claim 144, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 146 (depends on 144)

The compound of claim 144, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 147 (depends on 144)

The compound of claim 144, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 148 (depends on 144)

The compound of claim 144, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 149

A compound selected from
and, or a pharmaceutically acceptable salt thereof.

### Claim 150 (depends on 149)

The compound of claim 149, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 151 (depends on 149)

The compound of claim 149, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 152 (depends on 149)

The compound of claim 149, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 153 (depends on 139)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 139, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 154 (depends on 144)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 144, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 155 (depends on 149)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 149, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 156 (depends on 153)

The pharmaceutical composition of claim 153, further comprising one or more additional therapeutic agents.

### Claim 157 (depends on 154)

The pharmaceutical composition of claim 154, further comprising one or more additional therapeutic agents.

### Claim 158 (depends on 155)

The pharmaceutical composition of claim 155, further comprising one or more additional therapeutic agents.
